Novavax (NVAX) Cash from Operations Growth (3y) (2013 - 2026)
Novavax (NVAX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 33.08% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | 53.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.66% |
| Dec 31, 2025 | 30.54% |
| Sep 30, 2025 | 68.52% |
| Jun 30, 2025 | 9.30% |
| Mar 31, 2025 | -27.97% |
| Dec 31, 2024 | 20.33% |
| Sep 30, 2024 | -0.62% |
| Jun 30, 2024 | 29.59% |
| Mar 31, 2024 | -28.58% |
| Dec 31, 2023 | -11.20% |
| Sep 30, 2023 | -82.75% |
| Jun 30, 2023 | -51.64% |
| Mar 31, 2023 | -141.52% |
| Dec 31, 2022 | -70.56% |
| Sep 30, 2022 | -6.26% |
| Jun 30, 2022 | -78.57% |
| Mar 31, 2022 | -20.48% |
| Dec 31, 2021 | -96.30% |
| Sep 30, 2021 | -61.87% |
| Jun 30, 2021 | 77.72% |